Express Scripts' Earnings Made Easy

What do you need to know about Express Scripts' first-quarter results? These three highlights make understanding the PBM's earnings a piece of cake.

Apr 30, 2014 at 11:00AM


That's the simplest and probably most accurate one-word summary of Express Scripts' (NASDAQ:ESRX) first-quarter financial results. There's really not much attractive about the big pharmacy benefits manager's numbers. Here's what you need to know from the company's Tuesday announcement. 

1. Down, down, down
First-quarter revenue fell nearly 9% year over year to $23.685 billion. Net income dropped 12% from the same quarter in 2013 to $328.3 million. That translated to earnings per share of $0.42 on a generally accepted accounting principles basis. Adjusted earnings per diluted share were $0.99, which met the average estimate of analysts polled by Thomson Reuters but fell below the midpoint of the company's earlier first-quarter guidance. 

Esrx Logo

Source: Express Scripts

Express Scripts also revised its full-year 2014 guidance, which now calls for adjusted EPS between $4.82 and $4.94. The range previously given was $4.88-$5.

The primary reason behind the declining numbers wasn't unexpected. UnitedHealth Group (NYSE:UNH) completed its shift of pharmacy benefits management, or PBM, services to its own business unit, OptumRx, at the end of 2013. OptumRx is one of a handful of major competitors to Express Scripts.  

Factoring out the UnitedHealth effect does make year-over-year comparisons look more favorable. GAAP earnings per share in this case actually rose 11% versus the first quarter of 2013, with adjusted net income inching up by 1%.

2. Obamacare and Old Man Winter tag team
Adjusted prescription claims volume, though, dropped even with UnitedHealth's departure discounted. Express Scripts blamed the drop on an unusual tag team: Obamacare and the weather.

The company said that "later than expected enrollment in public exchanges and lower net new health care reform lives" were key contributing factors to the sluggish first-quarter results. Even though enrollment in the Obamacare online marketplace exchanges wound up ahead of the target level, many Americans waited until late in the game to sign up and weren't submitting prescription claims during the first three months of 2014. 

Regarding the weather impact, Express Scripts said only that "severe winter weather" accounted for some of the prescription claims volume shortfall. Reading between the lines: If people can't get out of their houses because of snow and ice, they can't get prescriptions filled.

3. Subpoenas a-flying
Express Scripts also stated in its SEC quarterly filing that it had received three subpoenas recently. The first came on Feb. 27 from the U.S. Justice Department's Rhode Island District. This inquiry requested information about the PBM's arrangements with several drugmakers, including Pfizer, Bayer, EMD Serono, and Biogen Idec. These companies market multiple sclerosis drugs.

The attorney general of New Jersey issued the second subpoena on March 31, requesting information about Express Scripts' relationship with AstraZeneca for heartburn and gastroesophageal reflux disease drug Nexium. Finally, the U.S. Department of Labor sent a subpoena on April 8 asking about client relationships dating back to 2009. 

Biogen Idec also referenced a federal subpoena in its 10-Q filing last week. The biotech only stated that the government asked for information about its "relationship with certain pharmacy benefit managers." Express Scripts wasn't mentioned by name. 

Easy call?
Shares of Express Scripts fell over 5% in after-hours trading Tuesday night. Is there an easy answer for investors wondering what to do? First, look at the factors behind the ugliness.

UnitedHealth's block of business has gone. That's been a given for a long time and shouldn't change anyone's thinking about Express Scripts as an investment option. The severe winter has also passed. There shouldn't be too many individuals holed up inside to the extent that they can't get prescriptions filled.

Likewise, the portion of the claims shortfall stemming from later than expected Obamacare enrollment is a temporary phenomenon. Lower overall net new enrollment from health reform could be a concern, but not enough in my view to affect Express Scripts and other major PBMs too much.

That leaves the subpoenas. No one knows what will happen on that front. Often, these requests for information don't lead to anything serious. Of course, sometimes they do. Remember, though, that even negative news stemming from government investigations in the past has not kept companies with solid business models from prospering over the long run.

Here's the easy call: If you like Express Scripts' business and the capability of its management team, stick with the stock. You'll probably win over the long run if you're right. If you don't, find another stock that meets those criteria. Every stock has an ugly period now and then. I suspect, however, that 10 years from now investors holding on to Express Scripts shares will be sitting pretty. 

Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Keith Speights owns shares of Express Scripts. The Motley Fool recommends Express Scripts and UnitedHealth Group. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers